Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 1.31 below Inventiva S A 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 348 other companies have achieved higher Quick Ratio than Inventiva S A in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 2019 to 2071.

Explain Quick Ratio?
How much Cash & cash equivalents IVA�s has?
What are IVA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IVA/financial-strength

https://api.csimarket.com/api/v1/companies/IVA/fundamentals

https://api.csimarket.com/api/v1/companies/IVA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

IVA Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-48.79 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	7.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.31	Subscribe	Subscribe	Subscribe	Subscribe
IVA's Total Ranking	# 2071	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 349
Healthcare Sector	# 636
Overall Market	# 2071

Quick Ratio Statistics
High	Average	Low
6.18	2.18	0.64
(Dec 31 2020)		(Dec 31 2023)

Financial Statements
Inventiva S A 's Current Liabilities	$ 87 Millions	Visit IVA's Balance sheet
Inventiva S A 's Cash & cash equivalent	$ 114 Millions	Visit IVA's Balance sheet
Source of IVA's Sales		Visit IVA's Sales by Geography

Cumulative Inventiva S A 's Quick Ratio

IVA's Quick Ratio for the trailling 12 Months

IVA Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-39.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	1.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.31	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3003	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-19.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	1.86 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to IVA Financial Strength Comparisons >> Go to Compare IVA Quick Ratio to its Competitors

On the trailing twelve months basis IVA Cash & cash equivalent improved by 7.87 % in Q4 2025 year on year, while Current Liabilities remained unchanged to $87 millions, this led to increase in in Inventiva S A 's Quick Ratio to 1.31, Quick Ratio remained below IVA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 373 other companies have achieved higher Quick Ratio than Inventiva S A . While Quick Ratio overall ranking has improved so far to 3003, from total ranking during the twelve months ending third quarter 2025 at 3716.

Explain Quick Ratio?
How much Cash & cash equivalents IVA�s has?
What are IVA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 374
Healthcare Sector	# 780
Within the Market	# 3003

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.79	2.39	0.64
(Dec 31 2021)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Genprex Inc	3.60	$ 7.831 Millions	$ 2.175 Millions
Cyclerion Therapeutics Inc	3.60	$ 3.240 Millions	$ 0.900 Millions
Forte Biosciences Inc	3.60	$ 76.957 Millions	$ 21.383 Millions
Cadrenal Therapeutics Inc	3.60	$ 5.710 Millions	$ 1.588 Millions
Renovorx Inc	3.58	$ 7.024 Millions	$ 1.962 Millions
Arrowhead Pharmaceuticals Inc	3.54	$ 692.818 Millions	$ 195.487 Millions
Syndax Pharmaceuticals Inc	3.44	$ 413.686 Millions	$ 120.116 Millions
Alumis inc	3.38	$ 308.501 Millions	$ 91.143 Millions
Quoin Pharmaceuticals Ltd	3.38	$ 18.745 Millions	$ 5.547 Millions
Rhythm Pharmaceuticals Inc	3.38	$ 388.949 Millions	$ 115.197 Millions
Biodexa Pharmaceuticals Plc	3.33	$ 11.599 Millions	$ 3.483 Millions
Urogen Pharma Ltd	3.32	$ 160.074 Millions	$ 48.225 Millions
Decoy Therapeutics Inc	3.29	$ 13.710 Millions	$ 4.166 Millions
Bolt Biotherapeutics Inc	3.26	$ 27.505 Millions	$ 8.435 Millions
Bullfrog Ai Holdings Inc	3.25	$ 2.184 Millions	$ 0.672 Millions
Inflarx N V	3.22	$ 20.403 Millions	$ 6.337 Millions
Madrigal Pharmaceuticals Inc	3.18	$ 983.559 Millions	$ 309.270 Millions
Aclaris Therapeutics Inc	3.17	$ 90.751 Millions	$ 28.645 Millions
Pyxis Oncology Inc	3.16	$ 66.857 Millions	$ 21.131 Millions
Skye Bioscience Inc	3.14	$ 25.737 Millions	$ 8.206 Millions
Acurx Pharmaceuticals inc	3.12	$ 7.556 Millions	$ 2.421 Millions
Gri Bio Inc	3.11	$ 8.229 Millions	$ 2.643 Millions
Cypherpunk Technologies Inc	3.11	$ 14.035 Millions	$ 4.520 Millions
Inhibitor Therapeutics Inc	3.10	$ 2.375 Millions	$ 0.766 Millions
Kyntra Bio Inc	3.04	$ 88.978 Millions	$ 29.242 Millions
Tao Synergies Inc	3.03	$ 5.498 Millions	$ 1.814 Millions
Kala Bio inc	3.03	$ 7.557 Millions	$ 2.494 Millions
Lb Pharmaceuticals Inc	3.01	$ 30.466 Millions	$ 10.126 Millions
Ardelyx inc	2.99	$ 264.689 Millions	$ 88.605 Millions
Kiniksa Pharmaceuticals International Plc	2.98	$ 414.074 Millions	$ 139.184 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.